Next Generation Drug Conjugates Market (2nd Edition) by Type of Drug Conjugate, Targeting Ligand, Payload, Route of Administration, Type of Therapy, Therapeutic Area, Geographical Regions, and Sales Forecast

As per Roots Analysis, the global next generation drug conjugates market is estimated to grow from USD 11.2 billion in the current year to USD 26.2 billion by 2035, at a CAGR of 9.9% during the forecast period, till 2035.

NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS

Next generation drug conjugates (XDCs) leverage diverse payloads, linker technologies, and targeting mechanisms to facilitate the precise delivery of therapeutic agents to diseased tissues while minimizing off-target toxicity. The incorporation of advanced chemical engineering techniques, innovative design approaches, and highly specific targeting modalities has significantly improved their therapeutic index and efficacy, enabling the development of more sophisticated, site-directed treatment options.

The next generation drug conjugates landscape is witnessing rapid expansion, supported by continuous advancements in payload technologies, including oligonucleotides, peptides, and small molecules, as well as innovations in linker design and conjugation platforms that enhance molecular stability and enable controlled drug release. However, despite these technological developments, challenges related to payload-target compatibility, manufacturing scalability, and physicochemical complexity continue to pose barriers to broader adoption and commercialization.

Growing application of XDCs across oncology, rare diseases, and immune-mediated disorders, coupled with increasing investments in precision medicine and multimodal therapeutic approaches, is expected to sustain market momentum. As a result, next generation drug conjugates are emerging as a highly promising and transformative segment within the broader conjugate therapeutics industry.

Growth Drivers: Strategic Enablers of Market Expansion

The next generation drug conjugates (XDCs) field is undergoing rapid evolution, driven by continuous advancements in targeting precision, payload innovation, and hybrid therapeutic design. Improvements in linker stability, payload potency, and targeted delivery technologies are enhancing the therapeutic index of XDCs, enabling more effective eradication of diseased cells while reducing off-target toxicity. At the same time, increasing interest in RNA-based therapeutics is accelerating innovation in oligonucleotide payloads, with developers focusing on improving molecular stability, intracellular delivery, and controlled-release capabilities to unlock new opportunities in precision gene regulation. Building on these advances, the emergence of hybrid XDCs that integrate multiple payload modalities, including small molecules, peptides, and oligonucleotides, is expanding the therapeutic potential of conjugate platforms. These next generation constructs can simultaneously address multiple disease pathways through dual- or multi-mechanism approaches, positioning XDCs as a transformative therapeutic class capable of overcoming the limitations of conventional monotherapies and addressing increasingly complex disease indications.

Market Challenges: Critical Barriers Impeding Progress

The next generation drug conjugates (XDCs) market continues to face several development and commercialization challenges despite ongoing technological advancements. A key obstacle is achieving optimal compatibility between payloads, linkers, and targeting moieties, as variations in biological targets and intracellular delivery pathways can impact therapeutic efficacy and safety. In addition, the increasing structural complexity of XDCs, particularly those incorporating novel payloads such as oligonucleotides, peptides, and multi-functional constructs, creates significant manufacturing and scalability challenges related to process consistency, quality control, and cost efficiency. Furthermore, the physicochemical complexity of these therapeutics can affect stability, formulation, and pharmacokinetic performance, while evolving regulatory requirements for emerging conjugate modalities often necessitate extensive characterization and validation efforts. Collectively, these factors can prolong development timelines, increase commercialization costs, and present barriers to the broader adoption of next generation drug conjugates.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS

The report delves into the current state of the next generation drug conjugates market and identifies potential growth opportunities within the industry. Some key findings from the report include:

1. More than 320 XDCs (~270 unique therapies) are currently approved / being investigated across various stages of development for various indications; of these, close to 60% are under different phases of clinical trials.

Next Generation Drug Conjugates Market - IMG1

2. Most (40%) of the XDC therapy programs are classified as ligand-drug conjugates; of these, over 95% function through sequence-specific target binding, ensuring covalent stability and exclusive payload delivery to target cells.

3 Most of the trials (~30%) were registered in H2 2025; notably, more than 70% of the registered trials are currently recruiting potential candidates for investigating next generation drug conjugates for various indications.

4. The growing interest in this industry is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to next generation drug conjugates were inked in 2021 and 2024.

Next Generation Drug Conjugates Market - IMG2

5. Close to 70% of the grants related to next generation drug conjugates were allocated for non-small business innovative research / small business technology transfer research.

6. The rising number of scientific articles being published in next generation drug conjugates market is indicative of the substantial efforts being undertaken by various stakeholders active in this domain.

7. 60% of the next generation drug conjugates were discontinued in Phase II of clinical trials; further, more than 45% of the conjugates that have been discontinued till date were ligand mediated RNAi conjugates.

8. The next generation drug conjugates market is likely to grow at an annualized rate (CAGR) of 9.9%, till 2035; notably, the ligand-mediated RNAi conjugates is anticipated to capture the majority share in the market by 2035.

9. Currently, majority of the market share is captured by the genetic disorders sub-segment; a substantial market share is expected to be captured by North America, by 2035.

Next Generation Drug Conjugates Market Segments

The market sizing and opportunity analysis has been segmented across the following parameters:

By Type of Drug Conjugate

Ligand Mediated RNAi Conjugates
Ligand Conjugated Antisense Medicines
Peptide-Radionuclide Conjugates
Small Molecule Drug Conjugates
Virus-like Drug Conjugates
Radioconjugates

By Type of Targeting Ligand

Amino Sugars
Peptides
Lipids
Virus-like Particles
Others

By Type of Payload

siRNAs
Radionuclides
Antisense Oligonucleotides
Drugs
Others

By Route of Administration

Subcutaneous
Intravenous
Suprachoroidal
Others

By Type of Therapy

Monotherapies
Combination Therapies
Others

By Therapeutic Area

Genetic Disorders
Oncological Disorders
Metabolic Disorders
Cardiovascular Disorders
Autoimmune Disorders
Hematological Disorders
Renal Disorders
Hepatic Disorders

By Geographical Regions

North America
- US
- Canada
Europe
- Germany
- Spain
- France
- UK
- Italy
Rest of Europe
Asia-Pacific
- China
- Japan
- Australia
- Rest of Asia-Pacific
Rest of the World
- Brazil
- Argentina
- Saudi Arabia

NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENT INSIGHTS

Ligand-Mediated RNAi Conjugates Driving Cancer Therapy Development

According to the next generation drug conjugates market forecast, ligand-mediated RNAi conjugates currently dominate the market with approximately 55% share, driven by increasing demand for therapies with enhanced efficacy and improved safety profiles.

Growth Potential of Virus-Like Drug Conjugates

Virus-like drug conjugates are projected to expand at a higher CAGR, indicating significant growth potential over the forecast period. This growth is attributed to their ability to mimic natural viral entry pathways, enabling highly efficient intracellular delivery of therapeutic payloads.

Subcutaneous Administration Driving Market Expansion

Based on market forecasts, subcutaneous administration accounts for more than 60% of current revenues across routes of administration. This dominance is supported by ease of administration, improved patient adherence, reduced reliance on hospital-based procedures, rising cancer prevalence, advancements in oncology precision medicine, and increasing R&D investments in the field.

Next Generation Drug Conjugate Monotherapies to Remain Dominant

According to market analysis, approximately 95% of next generation drug conjugates are currently prescribed as monotherapy, a trend expected to persist in the foreseeable future. This is primarily due to simplified dosing regimens, reduced toxicity, and suitability for long-term disease management and personalized treatment approaches. Recent approvals supporting this trend include GIVLAARI(R) (givosiran), OXLUMO(R) (lumasiran), Leqvio(R) (inclisiran), AMVUTTRA(R) (vutrisiran), PLUVICTO(R) (lutetium Lu 177 vipivotide tetraxetan), and Illuccix(R) (Ga-68 PSMA-11).

North America Dominating the Market Landscape

North America is expected to lead the next generation drug conjugates market, accounting for over 55% share by 2035. This dominance is driven by strong academia-industry collaborations, advanced manufacturing capabilities for complex conjugates, and a robust intellectual property framework. Notable approved XDCs in the region include GIVLAARI(R), DAWNZERA(TM), TRYNGOLZA(R), WAINZUA, and Lutathera, which generated approximately USD 0.8 billion in net sales in 2025.

Strong Growth Outlook for Europe

The European next generation drug conjugates market is projected to grow at a CAGR of approximately 14% over the forecast period. This growth is supported by the presence of leading biopharmaceutical companies such as Novartis, Novo Nordisk, AstraZeneca, and Bayer, which continue to strengthen innovation and development within the region.

Example Players in Next Generation Drug Conjugates Market

Alnylam Pharmaceuticals
Arrowhead Pharmaceuticals
Geron
Ionis Pharmaceuticals
Novartis
Novo Nordisk
Stemline Therapeutics
Telix Pharmaceuticals

Next Generation Drug Conjugates Market Experts

The opinions and insights presented in this study were influenced by discussions conducted with multiple stakeholders. The research report features detailed transcripts of the following third-party discussions:

Doctor of Medicine, Large Organization, Canada, North America
Doctor of Medicine, PhD, Large Organization, Spain, Europe
Vice President of Biologics Engineering and Tumor-Targeted Delivery, Large Organization, Europe
Surgical Oncologist, Cancer Research Organization, Denver, North America
Doctor of Medicine, Cancer Research Organization, US, North America
Chief Executive Officer, Large Organization, UK, Europe

NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE

Market Sizing and Opportunity Analysis: The report features an in-depth analysis of the next generation drug conjugates market, focusing on key market segments, including [A] type of drug conjugate, [B] type of targeting ligand, [C] type of payload, [D] route of administration, [E] type of therapy, [F] therapeutic area, [G] geographical regions, and [H] sales forecast.
Market Landscape: A detailed assessment of the overall next generation drug conjugates drugs landscape, featuring information on several relevant parameters, such as [A] stage of development, [B] type of conjugate, [C] mechanism of action, [D] type of therapy, [E] route of administration, [F] target indication, [G] therapeutic area, [H] target patient population [I] year of establishment, [J] company size, [K] location of headquarters, and [L] most active players.
Company Profiles: In-depth profiles of key drug developers in the next generation drug conjugate market, focusing on [A] company overview, [B] financial information, [C] drug portfolio, [D] recent developments and [E] an informed future outlook.
Clinical Trial Analysis: An analysis of completed and ongoing clinical trials related to next generation drug conjugates, based on several relevant parameters, such as [A] trial registration year, [B] enrolled patient population, [C] trial phase, [D] trial status, [E] type of sponsor / collaborator, [F] patient gender, [G] study design (type of trial masking, type of intervention model, trial purpose and design allocation), [H] leading industry and non-industry players (based on number of clinical trials) and [I] geography.
Partnerships and Collaborations: An analysis of partnerships and collaborations signed in the next generation drug conjugates market, based on several relevant parameters, such as [A] year of partnership, [B] type of partnership, [C] therapeutic area, [D] most active players, and [E] regional analysis.
Academic Grants Analysis: A comprehensive academic grants analysis, based on several parameters, such as [A] year of grant award, [B] amount awarded, [C] funding institute center, [D] support period, [E] type of grant application, [F] purpose of grant and [G] most popular recipient organizations.
Publication Analysis: An insightful publication analysis, based on several parameters, such as [A] year of publication, [B] type of publication, [C] most active publishers, and [D] most popular journals.
Drug Failure Analysis: An insightful drug failure analysis, based on several parameters, such as [A] trial phase, [B] trial status, [C] reason for drug discontinuation, [D] study start year, [E] year of discontinuation, [F] type of molecule, and [G] route of administration.
Success Protocol Analysis: An insightful analysis of recently approved next generation drug conjugates, based on several relevant parameters, such as [A] dosing frequency, [B] drug exclusivity, [C] safety and efficacy, [D] geographical reach, [E] intra-class competition, [F] line of treatment, [G] prevalence, [H] price, [I] type of therapy, and [J] existing competition among developers.

KEY QUESTIONS ANSWERED IN THIS REPORT

Which are the leading companies in the next generation drugs market?
Which region dominates the next generation drugs market?
What are the key trends observed in the next generation drugs market?
What factors are likely to influence the evolution of this market?
What are the primary challenges faced by next generation drug developers?
What is the current and future market size?
What is the CAGR of this market?
How is the current and future market opportunity likely to be distributed across key market segments?

REASONS TO BUY THIS REPORT

The report provides a comprehensive market analysis, offering detailed revenue projections of the overall market and its specific sub-segments. This information is valuable to both established market leaders and emerging entrants.
The report offers stakeholders a comprehensive overview of the market, including key drivers, barriers, opportunities, and challenges. This information empowers stakeholders to stay abreast of market trends and make data-driven decisions to capitalize on growth prospects.
The report can aid businesses in identifying future opportunities in any sector. It also helps in understanding if those opportunities are worth pursuing.
The report helps in identifying customer demand by understanding the needs, preferences, and behavior of the target audience in order to tailor products or services effectively.
The report equips new entrants with requisite information regarding a particular market to help them build successful business strategies.
The report allows for more effective communication with the audience and in building strong business relations.

ADDITIONAL BENEFITS

Complementary Excel Data Packs for all Analytical Modules in the Report
15% Free Content Customization
Detailed Report Walkthrough Session with Research Team
Free Updated report if the report is 6-12 months old or older

Product Code: RA100455

1. BACKGROUND

1.1. Context
1.2. Project Objectives

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
- 2.2.1. Market Landscape and Market Trends
- 2.2.2. Market Forecast and Opportunity Analysis
- 2.2.3. Comparative Analysis
2.3. Database Building
- 2.3.1. Data Collection
- 2.3.2. Data Validation
- 2.3.3. Data Analysis
2.4. Project Methodology
- 2.4.1. Secondary Research
  - 2.4.1.1. Annual Reports
  - 2.4.1.2. Academic Research Papers
  - 2.4.1.3. Company Websites
  - 2.4.1.4. Investor Presentations
  - 2.4.1.5. Regulatory Filings
  - 2.4.1.6. White Papers
  - 2.4.1.7. Industry Publications
  - 2.4.1.8. Conferences and Seminars
  - 2.4.1.9. Government Portals
  - 2.4.1.10. Media and Press Releases
  - 2.4.1.11. Newsletters
  - 2.4.1.12. Industry Databases
  - 2.4.1.13. Roots Proprietary Databases
  - 2.4.1.14. Paid Databases and Sources
  - 2.4.1.15. Social Media Portals
  - 2.4.1.16. Other Secondary Sources
- 2.4.2. Primary Research
  - 2.4.2.1. Types of Primary Research
    - 2.4.2.1.1. Qualitative Research
    - 2.4.2.1.2. Quantitative Research
    - 2.4.2.1.3. Hybrid Approach
  - 2.4.2.2. Advantages of Primary Research
  - 2.4.2.3. Techniques for Primary Research
    - 2.4.2.3.1. Interviews
    - 2.4.2.3.2. Surveys
    - 2.4.2.3.3. Focus Groups
    - 2.4.2.3.4. Observational Research
    - 2.4.2.3.5. Social Media Interactions
  - 2.4.2.4. Key Opinion Leaders Considered in Primary Research
    - 2.4.2.4.1. Company Executives (CXOs)
    - 2.4.2.4.2. Board of Directors
    - 2.4.2.4.3. Company Presidents and Vice Presidents
    - 2.4.2.4.4. Research and Development Heads
    - 2.4.2.4.5. Technical Experts
    - 2.4.2.4.6. Subject Matter Experts
    - 2.4.2.4.7. Scientists
    - 2.4.2.4.8. Doctors and Other Healthcare Providers
  - 2.4.2.5. Ethics and Integrity
    - 2.4.2.5.1. Research Ethics
    - 2.4.2.5.2. Data Integrity
- 2.4.3. Analytical Tools and Databases
2.5. Robust Quality Control

3. MARKET DYNAMICS

3.1. Chapter Overview
3.2. Forecast Methodology
- 3.2.1. Top-down Approach
- 3.2.2. Bottom-up Approach
- 3.2.3. Hybrid Approach
3.3. Market Assessment Framework
- 3.3.1. Total Addressable Market (TAM)
- 3.3.2. Serviceable Addressable Market (SAM)
- 3.3.3. Serviceable Obtainable Market (SOM)
- 3.3.4. Currently Acquired Market (CAM)
3.4. Forecasting Tools and Techniques
- 3.4.1. Qualitative Forecasting
- 3.4.2. Correlation
- 3.4.3. Regression
- 3.4.4. Extrapolation
- 3.4.5. Convergence
- 3.4.6. Sensitivity Analysis
- 3.4.7. Scenario Planning
- 3.4.8. Data Visualization
- 3.4.9. Time Series Analysis
- 3.4.10. Forecast Error Analysis
3.5. Key Considerations
- 3.5.1. Demographics
- 3.5.2. Government Regulations
- 3.5.3. Reimbursement Scenarios
- 3.5.4. Market Access
- 3.5.5. Supply Chain
- 3.5.6. Industry Consolidation
- 3.5.7. Pandemic / Unforeseen Disruptions Impact
3.6. Limitations

4. MACRO-ECONOMIC INDICATORS

4.1. Chapter Overview
4.2. Market Dynamics
- 4.2.1. Time Period
  - 4.2.1.1. Historical Trends
  - 4.2.1.2. Current and Forecasted Estimates
- 4.2.2. Currency Coverage
  - 4.2.2.1. Major Currencies Affecting the Market
  - 4.2.2.2. Factors Affecting Currency Fluctuations on the Industry
  - 4.2.2.3. Impact of Currency Fluctuations on the Industry
- 4.2.3. Foreign Currency Exchange Rate
  - 4.2.3.1. Impact of Foreign Exchange Rate Volatility on the Market
  - 4.2.3.2. Strategies for Mitigating Foreign Exchange Risk
- 4.2.4. Recession
  - 4.2.4.1. Assessment of Current Economic Conditions and Potential Impact on the Market
  - 4.2.4.2. Historical Analysis of Past Recessions and Lessons Learnt
- 4.2.5. Inflation
  - 4.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
  - 4.2.5.2. Potential Impact of Inflation on the Market Evolution
- 4.2.6. Interest Rates
  - 4.2.6.1. Interest Rates and Their Impact on the Market
  - 4.2.6.2. Strategies for Managing Interest Rate Risk
- 4.2.7. Commodity Flow Analysis
  - 4.2.7.1. Type of Commodity
  - 4.2.7.2. Origins and Destinations
  - 4.2.7.3. Values and Weights
  - 4.2.7.4. Modes of Transportation
- 4.2.8. Global Trade Dynamics
  - 4.2.8.1. Import Scenario
  - 4.2.8.2. Export Scenario
  - 4.2.8.3. Trade Policies
  - 4.2.8.4. Strategies for Mitigating the Risks Associated with Trade Barriers
  - 4.2.8.5. Impact of Trade Barriers on the Market
- 4.2.9. War Impact Analysis
  - 4.2.9.1. Russian-Ukraine War
  - 4.2.9.2. Israel-Hamas War
- 4.2.10. COVID Impact / Related Factors
  - 4.2.10.1. Global Economic Impact
  - 4.2.10.2. Industry-specific Impact
  - 4.2.10.3. Government Response and Stimulus Measures
  - 4.2.10.4. Future Outlook and Adaptation Strategies
- 4.2.11. Other Indicators
  - 4.2.11.1. Fiscal Policy
  - 4.2.11.2. Consumer Spending
  - 4.2.11.3. Gross Domestic Product
  - 4.2.11.4. Employment
  - 4.2.11.5. Taxes
  - 4.2.11.6. Stock Market Performance
  - 4.2.11.7. Cross Border Dynamics
4.3. Conclusion

5. EXECUTIVE SUMMARY

5.1. Executive Summary: Market Landscape
5.2. Executive Summary: Market Trends
5.3. Executive Summary: Market Forecast and Opportunity Analysis

6. INTRODUCTION

6.1. Chapter Overview
6.2. Overview of Next Generation Drug Conjugates
6.3. Key Historical Events
6.4. Structure of Next Generation Drug Conjugates
6.5. Biochemical Interaction and Mechanism of Action
6.6. Key Target Indications
6.7. Advantages of Next Generation Drug Conjugates
6.8. Challenges Associated with Next Generation Drug Conjugates
6.9. Future Perspective

7. MARKET LANDSCAPE

7.1. Methodology and Key Parameters
7.2. Next Generation Drug Conjugates: List of Therapy Programs
- 7.2.1. Analysis by Stage of Development
- 7.2.2. Analysis by Type of Conjugate
- 7.2.3. Analysis by Mechanism of Action
- 7.2.4. Analysis by Type of Therapy
- 7.2.5. Analysis by Route of Administration
- 7.2.6. Analysis by Target Indication
- 7.2.7. Analysis by Therapeutic Area
- 7.2.8. Analysis by Target Patient Population
7.3. Next Generation Drug Conjugates Therapy Programs: Developer Landscape
- 7.3.1. Analysis by Year of Establishment
- 7.3.2. Analysis by Company Size
- 7.3.3. Analysis by Location of Headquarters
- 7.3.4. Most Active Players: Analysis by Number of Next Generation Drug Conjugates

8. COMPANY PROFILES

8.1. Alnylam Pharmaceuticals
- 8.1.1. Company Overview
- 8.1.2. Management Team
- 8.1.3. Drug Portfolio
- 8.1.4. Key Initiatives
8.2. Arrowhead Pharmaceuticals
8.3. Geron
8.4. Ionis Pharmaceuticals
8.5. Novartis
8.6. Novo Nordisk
8.7. Stemline Therapeutics
8.8. Telix Pharmaceuticals

9. CLINICAL TRIAL ANALYSIS

9.1. Methodology and Key Parameters
9.2. Next Generation Drug Conjugates: Clinical Trial Analysis
- 9.2.1. Analysis by Trial Registration Year
- 9.2.2. Analysis by Trial Status
- 9.2.3. Analysis by Trial Registration Year and Trial Status
- 9.2.4. Analysis of Patient Enrolled by Trial Registration Year
- 9.2.5. Analysis by Trial Phase
- 9.2.6. Analysis of Patient Enrolled by Trial Phase
- 9.2.7. Analysis by Type of Sponsor / Collaborator
- 9.2.8. Analysis by Study Design
- 9.2.9. Analysis by Target Patient Population
- 9.2.10. Most Active Industry Players: Analysis by Number of Clinical Trials
- 9.2.11. Most Active Non-Industry Players: Analysis by Number of Clinical Trials
- 9.2.12. Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
- 9.2.13. Analysis by Trial Status and Geography
- 9.2.14. Analysis of Patients Enrolled by Trial Status and Geography

10. PARTNERSHIPS AND COLLABORATIONS

10.1. Methodology and Key Parameters
10.2. Partnership Models
10.3. Next Generation Drug Conjugates: Partnerships and Collaborations
- 10.3.1. Analysis by Year of Partnership
- 10.3.2. Analysis by Type of Partnership
- 10.3.3. Analysis by Year and Type of Partnership
- 10.3.4. Analysis by Therapeutic Area
- 10.3.5. Most Active Players: Analysis by Number of Partnerships
- 10.3.6. Analysis by Local and International Agreements
- 10.3.7. Analysis by Intercontinental and Intracontinental Agreements

11. ACADEMIC GRANTS ANALYSIS

11.1. Methodology and Key Parameters
11.2. Next Generation Drug Conjugates: Academic Grants Analysis
- 11.2.1. Analysis by Year of Grant Award
- 11.2.2. Analysis by Amount Awarded
- 11.2.3. Analysis by Funding Institute Center
- 11.2.4. Analysis by Support Period
- 11.2.5. Analysis by Funding Institute Center and Support Period
- 11.2.6. Analysis by Type of Grant Application
- 11.2.7. Analysis by Purpose of Grant
- 11.2.8. Analysis by Activity Code
- 11.2.9. Analysis by Study Section
- 11.2.10. Popular NIH Departments: Analysis by Number of Grants
- 11.2.11. Analysis by Type of Recipient Organization
  - 11.2.11.1. Most Popular Recipient Organizations: Analysis by Number of Grants
  - 11.2.11.2. Most Popular Recipient Organizations: Analysis by Amount Awarded
- 11.2.12. Prominent Program Officers: Analysis by Number of Grants
- 11.2.13. Analysis by Location of Recipient Organizations in the US

12. PUBLICATION ANALYSIS

12.1. Methodology and Key Parameters
12.2. Next Generation Drug Conjugates: Publication Analysis
- 12.2.1. Analysis by Year of Publication
- 12.2.2. Analysis by Type of Publication
- 12.2.3. Analysis by Year and Type of Publication
- 12.2.4. Most Active Publishers: Analysis by Number of Publications
- 12.2.5. Most Popular Journals: Analysis by Number of Publications
- 12.2.6. Most Popular Journals: Analysis by Impact Factor

13. DRUG FAILURE ANALYSIS

13.1. Methodology and Key Parameters
13.2. Next Generation Drug Conjugates: Drug Failure Analysis
- 13.2.1. Analysis by Trial Phase
- 13.2.2. Analysis by Trial Status
- 13.2.3. Analysis by Reason for Drug Discontinuation
- 13.2.4. Analysis by Study Start Year and Year of Discontinuation
- 13.2.5. Analysis by Target Indication
- 13.2.6. Analysis by Type of Conjugate
- 13.2.7. Analysis by Type of Sponsor / Collaborator

14. SUCCESS PROTOCOL ANALYSIS

14.1. Methodology and Key Parameters
14.2. Scoring Criteria
14.3. Success Protocol Analysis
14.4. Harvey Ball Analysis: Assessment of Approved Next Generation Drug Conjugates across Key Parameters

15. GLOBAL NEXT GENERATION DRUG CONJUGATES MARKET

15.1. Chapter Overview
15.2. Key Assumptions and Methodology
15.3. Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 15.3.1. Scenario Analysis
  - 15.3.1.1. Conservative Scenario
  - 15.3.1.2. Optimistic Scenario
15.4. Key Market Segmentations

16. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF CONJUGATE

16.1. Next Generation Drug Conjugates Market: Distribution by Type of Conjugate
- 16.1.1. Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 16.1.2. Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 16.1.3. Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 16.1.4. Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 16.1.5. Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 16.1.6. Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

17. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF TARGETING LIGAND

17.1. Next Generation Drug Conjugates Market: Distribution by Type of Targeting Ligand
- 17.1.1. Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 17.1.2. Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 17.1.3. Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 17.1.4. Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 17.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

18. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF PAYLOAD

18.1. Next Generation Drug Conjugates Market: Distribution by Type of Payload
- 18.1.1. Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 18.1.2. Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 18.1.3. Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 18.1.4. Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 18.1.5. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

19. NEXT GENERATION DRUG CONJUGATES MARKET, BY ROUTE OF ADMINISTRATION

19.1. Next Generation Drug Conjugates Market: Distribution by Route of Administration
- 19.1.1. Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 19.1.2. Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 19.1.3. Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 19.1.4. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

20. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF THERAPY

20.1. Next Generation Drug Conjugates Market: Distribution by Type of Therapy
- 20.1.1. Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 20.1.2. Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 20.1.3. Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

21. NEXT GENERATION DRUG CONJUGATES MARKET, BY THERAPEUTIC AREA

21.1. Next Generation Drug Conjugates Market: Distribution by Therapeutic Area
- 21.1.1. Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.2. Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.3. Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.4. Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.5. Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.6. Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.7. Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 21.1.8. Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

22. NEXT GENERATION DRUG CONJUGATES MARKET, BY GEOGRAPHICAL REGIONS

22.1. Next Generation Drug Conjugates Market: Distribution by Geographical Regions
- 22.1.1. Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  - 22.1.1.1. Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
  - 22.1.1.2. Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.2. Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.1. Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.2. Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.3. Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.4. Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.5. Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.2.6. Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.3. Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.3.1. Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.3.2. Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.3.3. Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.3.4. Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
22.4. Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.4.1. Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.4.2. Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 22.4.3. Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

23.1 Next Generation Drug Conjugates Market in North America: Distribution by Type of Conjugate
- 23.1.1. Next Generation Drug Conjugates Market in North America for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.1.2. Next Generation Drug Conjugates Market in North America for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.1.3. Next Generation Drug Conjugates Market in North America for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.1.4. Next Generation Drug Conjugates Market in North America for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.1.5. Next Generation Drug Conjugates Market in North America for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.1.6. Next Generation Drug Conjugates Market in North America for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.2. Next Generation Drug Conjugates Market in North America: Distribution by Type of Targeting Ligand
- 23.2.1. Next Generation Drug Conjugates Market in North America for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.2.2. Next Generation Drug Conjugates Market in North America for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.2.3. Next Generation Drug Conjugates Market in North America for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.2.4. Next Generation Drug Conjugates Market in North America for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.2.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.3. Next Generation Drug Conjugates Market in North America: Distribution by Type of Payload
- 23.3.1. Next Generation Drug Conjugates Market in North America for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.3.2. Next Generation Drug Conjugates Market in North America for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.3.3. Next Generation Drug Conjugates Market in North America for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.3.4. Next Generation Drug Conjugates Market in North America for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.3.5. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.4. Next Generation Drug Conjugates Market in North America: Distribution by Route of Administration
- 23.4.1. Next Generation Drug Conjugates Market in North America for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.4.2. Next Generation Drug Conjugates Market in North America for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.4.3. Next Generation Drug Conjugates Market in North America for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.4.4. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.5. Next Generation Drug Conjugates Market in North America: Distribution by Type of Therapy
- 23.5.1. Next Generation Drug Conjugates Market in North America for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.5.2. Next Generation Drug Conjugates Market in North America for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.5.3. Next Generation Drug Conjugates Market in North America for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
23.6. Next Generation Drug Conjugates Market in North America: Distribution by Therapeutic Area
- 23.6.1. Next Generation Drug Conjugates Market in North America for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.2. Next Generation Drug Conjugates Market in North America for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.3. Next Generation Drug Conjugates Market in North America for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.4. Next Generation Drug Conjugates Market in North America for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.5. Next Generation Drug Conjugates Market in North America for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.6. Next Generation Drug Conjugates Market in North America for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.7. Next Generation Drug Conjugates Market in North America for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 23.6.8. Next Generation Drug Conjugates Market in North America for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

24. MARKET OPPORTUNITY ANALYSIS: EUROPE

24.1 Next Generation Drug Conjugates Market in Europe: Distribution by Type of Conjugate
- 24.1.1 Next Generation Drug Conjugates Market in Europe for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.1.2. Next Generation Drug Conjugates Market in Europe for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.1.3. Next Generation Drug Conjugates Market in Europe for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.1.4. Next Generation Drug Conjugates Market in Europe for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.1.5. Next Generation Drug Conjugates Market in Europe for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.1.6. Next Generation Drug Conjugates Market in Europe for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.2. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Targeting Ligand
- 24.2.1. Next Generation Drug Conjugates Market in Europe for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.2.2. Next Generation Drug Conjugates Market in Europe for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.2.3. Next Generation Drug Conjugates Market in Europe for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.2.4. Next Generation Drug Conjugates Market in Europe for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.2.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.3. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Payload
- 24.3.1. Next Generation Drug Conjugates Market in Europe for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.3.2. Next Generation Drug Conjugates Market in Europe for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.3.3. Next Generation Drug Conjugates Market in Europe for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.3.4. Next Generation Drug Conjugates Market in Europe for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.3.5. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.4. Next Generation Drug Conjugates Market in Europe: Distribution by Route of Administration
- 24.4.1. Next Generation Drug Conjugates Market in Europe for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.4.2. Next Generation Drug Conjugates Market in Europe for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.4.3. Next Generation Drug Conjugates Market in Europe for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.4.4. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.5. Next Generation Drug Conjugates Market in Europe: Distribution by Type of Therapy
- 24.5.1. Next Generation Drug Conjugates Market in Europe for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.5.2. Next Generation Drug Conjugates Market in Europe for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.5.3. Next Generation Drug Conjugates Market in Europe for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
24.6. Next Generation Drug Conjugates Market in Europe: Distribution by Therapeutic Area
- 24.6.1. Next Generation Drug Conjugates Market in Europe for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.2. Next Generation Drug Conjugates Market in Europe for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.3. Next Generation Drug Conjugates Market in Europe for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.4. Next Generation Drug Conjugates Market in Europe for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.5. Next Generation Drug Conjugates Market in Europe for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.6. Next Generation Drug Conjugates Market in Europe for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.7. Next Generation Drug Conjugates Market in Europe for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 24.6.8. Next Generation Drug Conjugates Market in Europe for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

25.1 Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Conjugate
- 25.1.1. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.1.2. Next Generation Drug Conjugates Market in Asia-Pacific for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.1.3. Next Generation Drug Conjugates Market in Asia-Pacific for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.1.4. Next Generation Drug Conjugates Market in Asia-Pacific for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.1.5. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.1.6. Next Generation Drug Conjugates Market in Asia-Pacific for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.2. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Targeting Ligand
- 25.2.1. Next Generation Drug Conjugates Market in Asia-Pacific for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.2.2. Next Generation Drug Conjugates Market in Asia-Pacific for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.2.3. Next Generation Drug Conjugates Market in Asia-Pacific for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.2.4. Next Generation Drug Conjugates Market in Asia-Pacific for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.2.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.3. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Payload
- 25.3.1. Next Generation Drug Conjugates Market in Asia-Pacific for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.3.2. Next Generation Drug Conjugates Market in Asia-Pacific for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.3.3. Next Generation Drug Conjugates Market in Asia-Pacific for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.3.4. Next Generation Drug Conjugates Market in Asia-Pacific for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.3.5. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.4. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Route of Administration
- 25.4.1. Next Generation Drug Conjugates Market in Asia-Pacific for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.4.2. Next Generation Drug Conjugates Market in Asia-Pacific for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.4.3. Next Generation Drug Conjugates Market in Asia-Pacific for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.4.4. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.5. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Type of Therapy
- 25.5.1. Next Generation Drug Conjugates Market in Asia-Pacific for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.5.2. Next Generation Drug Conjugates Market in Asia-Pacific for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.5.3. Next Generation Drug Conjugates Market in Asia-Pacific for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
25.6. Next Generation Drug Conjugates Market in Asia-Pacific: Distribution by Therapeutic Area
- 25.6.1. Next Generation Drug Conjugates Market in Asia-Pacific for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.2. Next Generation Drug Conjugates Market in Asia-Pacific for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.3. Next Generation Drug Conjugates Market in Asia-Pacific for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.4. Next Generation Drug Conjugates Market in Asia-Pacific for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.5. Next Generation Drug Conjugates Market in Asia-Pacific for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.6. Next Generation Drug Conjugates Market in Asia-Pacific for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.7. Next Generation Drug Conjugates Market in Asia-Pacific for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 25.6.8. Next Generation Drug Conjugates Market in Asia-Pacific for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

26. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD

26.1 Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Conjugate
- 26.1.1. Next Generation Drug Conjugates Market in Rest of the World for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.1.2. Next Generation Drug Conjugates Market in Rest of the World for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.1.3. Next Generation Drug Conjugates Market in Rest of the World for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.1.4. Next Generation Drug Conjugates Market in Rest of the World for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.1.5. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.1.6. Next Generation Drug Conjugates Market in Rest of the World for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.2. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Targeting Ligand
- 26.2.1. Next Generation Drug Conjugates Market in Rest of the World for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.2.2. Next Generation Drug Conjugates Market in Rest of the World for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.2.3. Next Generation Drug Conjugates Market in Rest of the World for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.2.4. Next Generation Drug Conjugates Market in Rest of the World for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.2.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.3. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Payload
- 26.3.1. Next Generation Drug Conjugates Market in Rest of the World for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.3.2. Next Generation Drug Conjugates Market in Rest of the World for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.3.3. Next Generation Drug Conjugates Market in Rest of the World for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.3.4. Next Generation Drug Conjugates Market in Rest of the World for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.3.5. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.4. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Route of Administration
- 26.4.1. Next Generation Drug Conjugates Market in Rest of the World for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.4.2. Next Generation Drug Conjugates Market in Rest of the World for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.4.3. Next Generation Drug Conjugates Market in Rest of the World for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.4.4. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.5. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Type of Therapy
- 26.5.1. Next Generation Drug Conjugates Market in Rest of the World for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.5.2. Next Generation Drug Conjugates Market in Rest of the World for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.5.3. Next Generation Drug Conjugates Market in Rest of the World for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
26.6. Next Generation Drug Conjugates Market in Rest of the World: Distribution by Therapeutic Area
- 26.6.1. Next Generation Drug Conjugates Market in Rest of the World for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.2. Next Generation Drug Conjugates Market in Rest of the World for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.3. Next Generation Drug Conjugates Market in Rest of the World for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.4. Next Generation Drug Conjugates Market in Rest of the World for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.5. Next Generation Drug Conjugates Market in Rest of the World for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.6. Next Generation Drug Conjugates Market in Rest of the World for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.7. Next Generation Drug Conjugates Market in Rest of the World for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
- 26.6.8. Next Generation Drug Conjugates Market in Rest of the World for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)

27. NEXT GENERATION DRUG CONJUGATES MARKET: SALES FORECAST

27.1. AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02: Sales Forecast (USD Million)
27.2. AAA617 / PLUVICTO: Sales Forecast (USD Million)
27.3. Leqvio(R) / inclisiran: Sales Forecast (USD Million)
27.4. ARO-APOC3 / Plozasiran / REDEMPLO: Sales Forecast (USD Million)
27.5. Imetelstat: Sales Forecast (USD Million)
27.6. Qfitlia(TM) / Fitusiran: Sales Forecast (USD Million)
27.7. TRYNGOLZA(R) / olezarsen: Sales Forecast (USD Million)
27.8. WAINZUA / Eplontersen: Sales Forecast (USD Million)
27.9. Illuccix(R) (68Ga-PSMA-11): Sales Forecast (USD Million)
27.10. AAA601 / Lutathera(R): Sales Forecast (USD Million)
27.11. Gozellix(R): Sales Forecast (USD Million)
27.12. DAWNZERA(TM) / donidalorsen: Sales Forecast (USD Million)
27.13. OXLUMO(R) / lumasiran: Sales Forecast (USD Million)
27.14. GIVLAARI(R) / givosiran: Sales Forecast (USD Million)
27.15. LNTH-2501 / EVG-001: Sales Forecast (USD Million)
27.16. Pelacarsen: Sales Forecast (USD Million)
27.17. Cemdisiran: Sales Forecast (USD Million)
27.18. SAR-bis PSMA: Sales Forecast (USD Million)
27.19. RYZ-101: Sales Forecast (USD Million)
27.20. ARO-ANG3 / Zodasiran: Sales Forecast (USD Million)
27.21. Bel-sar / AU-011: Sales Forecast (USD Million)
27.22. RBD7022 / QLC7401: Sales Forecast (USD Million)

28. CONCLUDING INSIGHTS

29. EXECUTIVE INSIGHTS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

Product Code: RA100455

List of Tables

Table 7.1 List of Next Generation Drug Conjugates Therapy Programs
Table 7.2 List of Next Generation Drug Conjugate Developers
Table 9.1 Next Generation Drug Conjugate Therapy Programs: List of Clinical Trials, (Since 2024)
Table 10.1 Next Generation Drug Conjugates Market: List of Partnerships and Collaborations, (Since 2018)
Table 11.1 Next Generation Drug Conjugates: List of Academic Grants, (Since 2018)
Table 12.1 Next Generation Drug Conjugates Market: List of Publications, (Since 2020)
Table 13.1 List of Discontinued Next Generation Drug Conjugates
Table 15.1 Next Generation Drug Conjugates Market, Till 2035
Table 25.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development
Table 25.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate
Table 25.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action
Table 25.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy
Table 25.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration
Table 25.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication
Table 25.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area
Table 25.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Target Patient Population
Table 25.9 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Table 25.10 Next Generation Drug Conjugate Developers: Distribution by Company Size
Table 25.11 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters
Table 25.12 Next Generation Drug Conjugate Developers: Most Active Players: Distribution by Number of Next Generation Drug Conjugates
Table 25.13 Clinical Trial Analysis: Analysis by Trial Registration Year (Since 2024)
Table 25.14 Clinical Trial Analysis: Analysis by Trial Status
Table 25.15 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
Table 25.16 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
Table 25.17 Clinical Trial Analysis: Analysis by Trial Phase
Table 25.18 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
Table 25.19 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
Table 25.20 Clinical Trial Analysis: Analysis by Study Design
Table 25.21 Clinical Trial Analysis: Analysis by Target Patient Population
Table 25.22 Clinical Trial Analysis: Most Active Industry Players: Analysis by Number of Clinical Trials
Table 25.23 Clinical Trial Analysis: Most Active Non-Industry Players: Analysis by Number of Clinical Trials
Table 25.24 Clinical Trial Analysis: Analysis by Number of Clinical Trials and Patient Enrolled
Table 25.25 Clinical Trial Analysis: Analysis by Number of Trials by Trial Status and Geography
Table 25.26 Clinical Trial Analysis: Analysis by Trial Status and Geography
Table 25.27 Clinical Trial Analysis: Analysis of Number of Patients Enrolled by Trial Status and Geography
Table 25.28 Partnerships and Collaborations: Analysis by Year of Partnership
Table 25.29 Partnerships and Collaborations: Analysis by Type of Partnership
Table 25.30 Partnerships and Collaborations: Analysis by Year and Type of Partnership
Table 25.31 Partnerships and Collaborations: Analysis by Therapeutic Area
Table 25.32 Partnerships and Collaborations: Most Active Players: Analysis by Number of Partnerships
Table 25.33 Partnerships and Collaborations: Analysis by Local and International Agreements
Table 25.34 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
Table 25.35 Academic Grants Analysis: Analysis by Year of Grant Award
Table 25.36 Academic Grants Analysis: Analysis by Amount Awarded (USD Million)
Table 25.37 Academic Grants Analysis: Analysis by Funding Institute Center
Table 25.38 Academic Grants Analysis: Analysis by Support Period
Table 25.39 Academic Grants Analysis: Funding Institute Center and Support Period
Table 25.40 Academic Grants Analysis: Analysis by Type of Grant Application
Table 25.41 Academic Grants Analysis: Analysis by Purpose of Grant
Table 25.42 Academic Grants Analysis: Analysis by Activity Code
Table 25.43 Academic Grants Analysis: Analysis by Study Section
Table 25.44 Academic Grants Analysis: Most Popular NIH Departments: Analysis by Number of Grants
Table 25.45 Academic Grants Analysis: Type of Recipient Organization
Table 25.46 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Number of Grants
Table 25.47 Academic Grants Analysis: Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
Table 25.48 Academic Grants Analysis: Prominent Program Officers: Analysis by Number of Grants
Table 25.49 Academic Grants Analysis: Prominent Program Officers: Location of Recipient Organizations in the US
Table 25.50 Publication Analysis: Analysis by Year of Publication, Since 2020
Table 25.51 Publication Analysis: Analysis by Type of Publication
Table 25.52 Publication Analysis: Analysis by Year and Type of Publication, Since 2020
Table 25.53 Most Active Publishers: Analysis by Number of Publications
Table 25.54 Most Popular Journals: Analysis by Number of Publications
Table 25.55 Most Popular Journals: Analysis by Impact Factor
Table 25.56 Drug Failure Analysis: Analysis by Trial Phase
Table 25.57 Drug Failure Analysis: Analysis by Trial Status
Table 25.58 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation
Table 25.59 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation
Table 25.60 Drug Failure Analysis: Analysis by Target Indication
Table 25.61 Drug Failure Analysis: Analysis by Type of Conjugate
Table 25.62 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator
Table 25.63 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis
Table 25.64 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario
Table 25.65 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario
Table 25.66 Global Next Generation Drug Conjugates Market, Analysis by Type of Conjugate
Table 25.67 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.68 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.69 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.70 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.71 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Forecasted Estimates (Till 2035)
Table 25.72 Next Generation Drug Conjugates Market for Radioconjugates Forecasted Estimates (Till 2035)
Table 25.73 Global Next Generation Drug Conjugates Market, Analysis by Type of Targeting Ligand
Table 25.74 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.75 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.76 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.77 Next Generation Drug Conjugates Market for Virus-like Particles, Forecasted Estimates (Till 2035)
Table 25.78 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035)
Table 25.79 Global Next Generation Drug Conjugates Market, Analysis by Type of Payload
Table 25.80 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.81 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.82 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.83 Next Generation Drug Conjugates Market for Drugs, Forecasted Estimates (Till 2035)
Table 25.84 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2035)
Table 25.85 Global Next Generation Drug Conjugates Market, Analysis by Route of Administration
Table 25.86 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.87 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.88 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.89 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.90 Global Next Generation Drug Conjugates Market, Analysis by Type of Therapy
Table 25.91 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535)
Table 25.92 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2535)
Table 25.93 Next Generation Drug Conjugates Market for Others, Forecasted Estimates (Till 2535)
Table 25.94 Global Next Generation Drug Conjugates Market, Analysis by Therapeutic Area
Table 25.95 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.96 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.97 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.98 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Forecasted Estimates (Till 2035)
Table 25.99 Next Generation Drug Conjugates Market for Autoimmune Disorders, Forecasted Estimates (Till 2035)
Table 25.100 Next Generation Drug Conjugates Market for Hematological Disorders, Forecasted Estimates (Till 2035)
Table 25.101 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.102 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.103 Global Next Generation Drug Conjugates Market, Analysis by Geographical Regions
Table 25.104 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.105 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.106 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.107 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.108 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.109 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.110 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.111 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.112 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.113 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.114 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.115 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.116 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.117 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.118 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.119 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.120 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.121 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.122 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Table 25.123 Next Generation Drug Conjugate Market for AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.124 Next Generation Drug Conjugates Market for AAA617 / PLUVICTO, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.125 Next Generation Drug Conjugates Market for Leqvio(R) / inclisiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.126 Next Generation Drug Conjugates Market for ARO-APOC3 / Plozasiran / REDEMPLO, Forecasted Estimates (Till 2035) (USD Million)
Table 25.127 Next Generation Drug Conjugates Market for Imetelstat, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.128 Next Generation Drug Conjugates Market for Qfitlia(TM) / Fitusiran, Forecasted Estimates (Till 2035) (USD Million)
Table 25.129 Next Generation Drug Conjugates Market for TRYNGOLZA(R) / olezarsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.130 Next Generation Drug Conjugates Market for WAINZUA / Eplontersen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.131 Next Generation Drug Conjugates Market for Illuccix(R) (68Ga-PSMA-11), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.132 Next Generation Drug Conjugates Market for AAA601 / Lutathera(R), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.133 Next Generation Drug Conjugates Market for Gozellix(R), Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.134 Next Generation Drug Conjugates Market for DAWNZERA(TM) / donidalorsen, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.135 Next Generation Drug Conjugates Market for OXLUMO(R) / lumasiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.136 Next Generation Drug Conjugates Market for GIVLAARI(R) / givosiran, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035) (USD Million)
Table 25.137 Next Generation Drug Conjugates Market for LNTH-2501 / EVG-001, Forecasted Estimates (Till 2035) (USD Million)
Table 25.138 Next Generation Drug Conjugates Market for Pelacarsen, Forecasted Estimates (Till 2035) (USD Million)
Table 25.139 Next Generation Drug Conjugates Market for Cemdisiran, Forecasted Estimates (Till 2035) (USD Million)
Table 25.140 Next Generation Drug Conjugates Market for SAR-bis PSMA, Forecasted Estimates (Till 2035) (USD Million)
Table 25.141 Next Generation Drug Conjugates Market for RYZ-101, Forecasted Estimates (Till 2035) (USD Million)
Table 25.142 Next Generation Drug Conjugates Market for ARO-ANG3 / Zodasiran, Forecasted Estimates (Till 2035) (USD Million)
Table 25.143 Next Generation Drug Conjugates Market for Bel-sar / AU-011, Forecasted Estimates (Till 2035) (USD Million)
Table 25.144 Next Generation Drug Conjugates Market for RBD7022 / QLC7401, Forecasted Estimates (Till 2035) (USD Million)

List of Figures

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Data Sources for Secondary Research
Figure 2.3 Research Methodology: Robust Quality Control
Figure 3.1 Market Dynamics: Forecast Methodology
Figure 3.2 Market Dynamics: Market Assessment Framework
Figure 3.3 Market Dynamics: Example List of Parameters
Figure 4.1 Historical Analysis of Past Recessions and Lessons Learnt
Figure 5.1 Executive Summary: Market Landscape
Figure 5.2 Executive Summary: Market Trends
Figure 5.3 Executive Summary: Market Sizing and Opportunity Analysis
Figure 6.1 Structure of Next Generation Drug Conjugates
Figure 6.2 Biochemical Interaction and Mechanism of Action
Figure 7.1 Next Generation Drug Conjugate Therapy Programs: Distribution by Stage of Development
Figure 7.2 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Conjugate
Figure 7.3 Next Generation Drug Conjugate Therapy Programs: Distribution by Mechanism of Action
Figure 7.4 Next Generation Drug Conjugate Therapy Programs: Distribution by Type of Therapy
Figure 7.5 Next Generation Drug Conjugate Therapy Programs: Distribution by Route of Administration
Figure 7.6 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Indication
Figure 7.7 Next Generation Drug Conjugate Therapy Programs: Distribution by Therapeutic Area
Figure 7.8 Next Generation Drug Conjugate Therapy Programs: Distribution by Target Patient Population
Figure 7.9 Next Generation Drug Conjugate Developers: Distribution by Location of Headquarters
Figure 7.10 Next Generation Drug Conjugate Developers: Distribution by Year of Establishment
Figure 7.11 Next Generation Drug Conjugate Developers: Distribution by Company Size
Figure 7.12 Most Active Players: Distribution by Number of Next Generation Drug Conjugates
Figure 9.1 Clinical Trial Analysis: Analysis by Trial Registration Year
Figure 9.2 Clinical Trial Analysis: Analysis by Trial Status
Figure 9.3 Clinical Trial Analysis: Analysis by Trial Registration Year and Trial Status
Figure 9.4 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Registration Year
Figure 9.5 Clinical Trial Analysis: Analysis by Trial Phase
Figure 9.6 Clinical Trial Analysis: Analysis of Patient Enrolled by Trial Phase
Figure 9.7 Clinical Trial Analysis: Analysis by Type of Sponsor / Collaborator
Figure 9.8 Clinical Trial Analysis: Analysis by Study Design
Figure 9.9 Clinical Trial Analysis: Analysis by Target Patient Population
Figure 9.10 Most Active Industry Players: Analysis by Number of Clinical Trials
Figure 9.11 Most Active Non- Industry Players: Analysis by Number of Clinical Trials
Figure 9.12 Geographical Distribution: Analysis by Number of Trials and Patients Enrolled
Figure 9.13 Clinical Trial Analysis: Analysis by Trial Status and Geography
Figure 9.14 Clinical Trial Analysis: Analysis of Patients Enrolled by Trial Status and Geography
Figure 10.1 Partnerships and Collaborations: Analysis by Year of Partnership
Figure 10.2 Partnerships and Collaborations: Analysis by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Analysis by Year and Type of Partnership
Figure 10.4 Partnerships and Collaborations: Analysis by Therapeutic Area
Figure 10.5 Most Active Players: Analysis by Number of Partnerships
Figure 10.6 Partnerships and Collaborations: Analysis by Local and International Agreements
Figure 10.7 Partnerships and Collaborations: Analysis by Intercontinental and Intracontinental Agreements
Figure 11.1 Academic Grants Analysis: Analysis by Year of Grant Award
Figure 11.2 Academic Grants Analysis: Analysis by Amount Awarded
Figure 11.3 Academic Grants Analysis: Analysis by Funding Institute Center
Figure 11.4 Academic Grants Analysis: Analysis by Support Period
Figure 11.5 Academic Grants Analysis: Analysis by Funding Institute Center and Support Period
Figure 11.6 Academic Grants Analysis: Analysis by Type of Grant Application
Figure 11.7 Academic Grants Analysis: Analysis by Purpose of Grant
Figure 11.8 Academic Grants Analysis: Analysis by Activity Code
Figure 11.9 Academic Grants Analysis: Analysis by Study Section
Figure 11.10 Popular NIH Departments: Analysis by Number of Grants
Figure 11.11 Academic Grants Analysis: Analysis by Type of Recipient Organization
Figure 11.12 Popular Recipient Organizations: Analysis by Number of Grants
Figure 11.13 Popular Recipient Organizations: Analysis by Amount Awarded (USD Million)
Figure 11.14 Prominent Program Officers: Analysis by Number of Grants
Figure 11.15 Academic Grants Analysis: Analysis by Location of Recipient Organization in the US
Figure 12.1 Publication Analysis: Analysis by Year of Publication
Figure 12.2 Publication Analysis: Analysis by Type of Publication
Figure 12.3 Publication Analysis: Analysis by Year and Type of Publication
Figure 12.4 Most Active Publishers: Analysis by Number of Publications
Figure 12.5 Most Popular Journals: Analysis by Number of Publications
Figure 12.6 Most Popular Journals: Analysis by Impact Factor
Figure 13.1 Drug Failure Analysis: Analysis by Trial Phase
Figure 13.2 Drug Failure Analysis: Analysis by Trial Status
Figure 13.3 Drug Failure Analysis: Analysis by Reason for Drug Discontinuation
Figure 13.4 Drug Failure Analysis: Analysis by Study Start Year and Year of Discontinuation
Figure 13.5 Drug Failure Analysis: Analysis by Target Indication
Figure 13.6 Drug Failure Analysis: Analysis by Type of Conjugate
Figure 13.7 Drug Failure Analysis: Analysis by Type of Sponsor / Collaborator
Figure 14.1 Success Protocol Analysis: Spider Web Analysis for Lutathera
Figure 14.2 Success Protocol Analysis: Spider Web Analysis for Pluvicto
Figure 14.3 Success Protocol Analysis: Spider Web Analysis for Givlaari
Figure 14.4 Success Protocol Analysis: Spider Web Analysis for Oxlumo
Figure 14.5 Success Protocol Analysis: Spider Web Analysis for Amvuttra
Figure 14.6 Success Protocol Analysis: Spider Web Analysis for Leqvio
Figure 14.7 Harvey Ball Analysis: Assessment of Approved Next Generation Drug Conjugates across Key Parameters
Figure 15.1 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Scenario Analysis
Figure 15.2 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Conservative Scenario
Figure 15.3 Global Next Generation Drug Conjugates Market, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035), Optimistic Scenario
Figure 16.1 Next Generation Drug Conjugates Market for Ligand Mediated RNAi Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 16.2 Next Generation Drug Conjugates Market for Ligand Conjugated Antisense Medicines, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 16.3 Next Generation Drug Conjugates Market for Peptide-Radionuclide Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 16.4 Next Generation Drug Conjugates Market for Small Molecule Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 16.5 Next Generation Drug Conjugates Market for Virus-like Drug Conjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 16.6 Next Generation Drug Conjugates Market for Radioconjugates, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 17.1 Next Generation Drug Conjugates Market for Amino Sugars, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 17.2 Next Generation Drug Conjugates Market for Peptides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 17.3 Next Generation Drug Conjugates Market for Lipids, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 17.4 Next Generation Drug Conjugates Market for Virus-like Particles, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 17.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 18.1 Next Generation Drug Conjugates Market for siRNAs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 18.2 Next Generation Drug Conjugates Market for Radionuclides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 18.3 Next Generation Drug Conjugates Market for Antisense Oligonucleotides, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 18.4 Next Generation Drug Conjugates Market for Drugs, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 18.5 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 19.1 Next Generation Drug Conjugates Market for Subcutaneous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 19.2 Next Generation Drug Conjugates Market for Intravenous, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 19.3 Next Generation Drug Conjugates Market for Suprachoroidal, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 19.4 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 20.1 Next Generation Drug Conjugates Market for Monotherapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 20.2 Next Generation Drug Conjugates Market for Combination Therapies, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 20.3 Next Generation Drug Conjugates Market for Others, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.1 Next Generation Drug Conjugates Market for Genetic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.2 Next Generation Drug Conjugates Market for Oncological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.3 Next Generation Drug Conjugates Market for Metabolic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.4 Next Generation Drug Conjugates Market for Cardiovascular Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.5 Next Generation Drug Conjugates Market for Autoimmune Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.6 Next Generation Drug Conjugates Market for Hematological Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.7 Next Generation Drug Conjugates Market for Renal Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 21.8 Next Generation Drug Conjugates Market for Hepatic Disorders, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.1 Next Generation Drug Conjugates Market in North America, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.2 Next Generation Drug Conjugates Market in the US, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.3 Next Generation Drug Conjugates Market in Canada, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.4 Next Generation Drug Conjugates Market in Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.5 Next Generation Drug Conjugates Market in Germany, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.6 Next Generation Drug Conjugates Market in Spain, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.7 Next Generation Drug Conjugates Market in France, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.8 Next Generation Drug Conjugates Market in the UK, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.9 Next Generation Drug Conjugates Market in Italy, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.10 Next Generation Drug Conjugates Market in Rest of Europe, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.11 Next Generation Drug Conjugates Market in Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.12 Next Generation Drug Conjugates Market in China, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.13 Next Generation Drug Conjugates Market in Japan, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.14 Next Generation Drug Conjugates Market in Australia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.15 Next Generation Drug Conjugates Market in Rest of Asia-Pacific, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.16 Next Generation Drug Conjugates Market in Rest of the World, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.17 Next Generation Drug Conjugates Market in Brazil, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.18 Next Generation Drug Conjugates Market in Argentina, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 22.19 Next Generation Drug Conjugates Market in Saudi Arabia, Historical Trends (Since 2023) and Forecasted Estimates (Till 2035)
Figure 23.1 Next Generation Drug Conjugates Market: Sales Forecast for AMVUTTRA(R) / Vutrisiran / ALN-TTRSC04 / ALN-TTRSC02 (USD Million)
Figure 23.2 Next Generation Drug Conjugates Market: Sales Forecast for AAA617 / PLUVICTO (USD Million)
Figure 23.3 Next Generation Drug Conjugates Market: Sales Forecast for Leqvio(R) / inclisiran (USD Million)
Figure 23.4 Next Generation Drug Conjugates Market: Sales Forecast for ARO-APOC3 / Plozasiran / REDEMPLO (USD Million)
Figure 23.5 Next Generation Drug Conjugates Market: Sales Forecast for Imetelstat (USD Million)
Figure 23.6 Next Generation Drug Conjugates Market: Sales Forecast for Qfitlia(TM) / Fitusiran (USD Million)
Figure 23.7 Next Generation Drug Conjugates Market: Sales Forecast for TRYNGOLZA(R) / olezarsen (USD Million)
Figure 23.8 Next Generation Drug Conjugates Market: Sales Forecast for WAINZUA / Eplontersen (USD Million)
Figure 23.9 Next Generation Drug Conjugates Market: Sales Forecast for Illuccix(R) (68Ga-PSMA-11) (USD Million)
Figure 23.10 Next Generation Drug Conjugates Market: Sales Forecast for AAA601 / Lutathera(R) (USD Million)
Figure 23.11 Next Generation Drug Conjugates Market: Sales Forecast for Gozellix(R) (USD Million)
Figure 23.12 Next Generation Drug Conjugates Market: Sales Forecast for DAWNZERA(TM) / donidalorsen (USD Million)
Figure 23.13 Next Generation Drug Conjugates Market: Sales Forecast for OXLUMO(R) / lumasiran (USD Million)
Figure 23.14 Next Generation Drug Conjugates Market: Sales Forecast for GIVLAARI(R) / givosiran (USD Million)
Figure 23.15 Next Generation Drug Conjugates Market: Sales Forecast for LNTH-2501 / EVG-001 (USD Million)
Figure 23.16 Next Generation Drug Conjugates Market: Sales Forecast for Pelacarsen (USD Million)
Figure 23.17 Next Generation Drug Conjugates Market: Sales Forecast for Cemdisiran (USD Million)
Figure 23.18 Next Generation Drug Conjugates Market: Sales Forecast for SAR-bis PSMA (USD Million)
Figure 23.19 Next Generation Drug Conjugates Market: Sales Forecast for RYZ-101 (USD Million)
Figure 23.20 Next Generation Drug Conjugates Market: Sales Forecast for ARO-ANG3 / Zodasiran (USD Million)
Figure 23.21 Next Generation Drug Conjugates Market: Sales Forecast for Bel-sar / AU-011 (USD Million)
Figure 23.22 Next Generation Drug Conjugates Market: Sales Forecast for RBD7022 / QLC7401 (USD Million)

Next Generation Drug Conjugates Market (2nd Edition) by Type of Drug Conjugate, Targeting Ligand, Payload, Route of Administration, Type of Therapy, Therapeutic Area, Geographical Regions, and Sales Forecast - Trends and Forecast, Till 2035

Description

Table of Contents

List of Tables

NEXT GENERATION DRUG CONJUGATES MARKET: OVERVIEW

NEXT GENERATION DRUG CONJUGATES MARKET: GROWTH AND TRENDS

NEXT GENERATION DRUG CONJUGATES MARKET: KEY INSIGHTS

1. More than 320 XDCs (~270 unique therapies) are currently approved / being investigated across various stages of development for various indications; of these, close to 60% are under different phases of clinical trials.

2. Most (40%) of the XDC therapy programs are classified as ligand-drug conjugates; of these, over 95% function through sequence-specific target binding, ensuring covalent stability and exclusive payload delivery to target cells.

3 Most of the trials (~30%) were registered in H2 2025; notably, more than 70% of the registered trials are currently recruiting potential candidates for investigating next generation drug conjugates for various indications.

4. The growing interest in this industry is evident from the rise in partnership activity; in fact, the maximum number of collaborations related to next generation drug conjugates were inked in 2021 and 2024.

5. Close to 70% of the grants related to next generation drug conjugates were allocated for non-small business innovative research / small business technology transfer research.

6. The rising number of scientific articles being published in next generation drug conjugates market is indicative of the substantial efforts being undertaken by various stakeholders active in this domain.

7. 60% of the next generation drug conjugates were discontinued in Phase II of clinical trials; further, more than 45% of the conjugates that have been discontinued till date were ligand mediated RNAi conjugates.

8. The next generation drug conjugates market is likely to grow at an annualized rate (CAGR) of 9.9%, till 2035; notably, the ligand-mediated RNAi conjugates is anticipated to capture the majority share in the market by 2035.

9. Currently, majority of the market share is captured by the genetic disorders sub-segment; a substantial market share is expected to be captured by North America, by 2035.

NEXT GENERATION DRUG CONJUGATES MARKET: KEY SEGMENT INSIGHTS

Example Players in Next Generation Drug Conjugates Market

NEXT GENERATION DRUG CONJUGATES MARKET: RESEARCH COVERAGE

KEY QUESTIONS ANSWERED IN THIS REPORT

REASONS TO BUY THIS REPORT

TABLE OF CONTENTS

1. BACKGROUND

2. RESEARCH METHODOLOGY

3. MARKET DYNAMICS

4. MACRO-ECONOMIC INDICATORS

5. EXECUTIVE SUMMARY

6. INTRODUCTION

7. MARKET LANDSCAPE

8. COMPANY PROFILES

9. CLINICAL TRIAL ANALYSIS

10. PARTNERSHIPS AND COLLABORATIONS

11. ACADEMIC GRANTS ANALYSIS

12. PUBLICATION ANALYSIS

13. DRUG FAILURE ANALYSIS

14. SUCCESS PROTOCOL ANALYSIS

15. GLOBAL NEXT GENERATION DRUG CONJUGATES MARKET

16. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF CONJUGATE

17. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF TARGETING LIGAND

18. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF PAYLOAD

19. NEXT GENERATION DRUG CONJUGATES MARKET, BY ROUTE OF ADMINISTRATION

20. NEXT GENERATION DRUG CONJUGATES MARKET, BY TYPE OF THERAPY

21. NEXT GENERATION DRUG CONJUGATES MARKET, BY THERAPEUTIC AREA

22. NEXT GENERATION DRUG CONJUGATES MARKET, BY GEOGRAPHICAL REGIONS

23. MARKET OPPORTUNITY ANALYSIS: NORTH AMERICA

24. MARKET OPPORTUNITY ANALYSIS: EUROPE

25. MARKET OPPORTUNITY ANALYSIS: ASIA-PACIFIC

26. MARKET OPPORTUNITY ANALYSIS: REST OF THE WORLD

27. NEXT GENERATION DRUG CONJUGATES MARKET: SALES FORECAST

28. CONCLUDING INSIGHTS

29. EXECUTIVE INSIGHTS

30. APPENDIX 1: TABULATED DATA

31. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

List of Tables

List of Figures